articleThe Lancet Respiratory MedicineDec 18, 2020Closed access

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Tongji University · Shanghai Pulmonary Hospital · +37 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

501
total citations
FWCI
24.98
Percentile
100%
References
27
Citations per year

Authors

36

Topics & keywords

Keywords
  • Pemetrexed
  • Medicine
  • Carboplatin
  • Internal medicine
  • Oncology
  • Lung cancer
  • Chemotherapy
  • Response Evaluation Criteria in Solid Tumors
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.